Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Chronic hepatitis C genotype 1 infection, diagnosed at least 6 months prior to screening~2. Confirmed prior virological failure with an approved dose of PegIFN/RBV~3. Age 18 to 70 years,~4. HCV RNA (RiboNucleic Acid) = 1,000 IU/mL at screening,~Exclusion criteria:~1. HCV infection of mixed genotype; Hepatitis B Virus (HBV) or Human Immunodeficiency Virus (HIV) co-infection~2. Evidence of acute or chronic liver disease due to causes other than chronic HCV infection,~3. Decompensated liver disease, or history of decompensated liver disease,~4. Body weight \< 40 or \> 125 kg,~5. Clinical evidence of significant or unstable cardiovascular disease, chronic pulmonary disease, history or evidence of retinopathy or clinically significant ophthalmological disorder~6. Pre-existing psychiatric condition that could interfere with the subject's participation in and completion of the study~7. Laboratory parameters disorders (thalassemia major, sickle cell anemia or G6PD deficit)~8. Hemoglobin \< 12 g/dL for women and \< 13 g/dL for men~9. Patients who have been previously treated with at least one dose of any antiviral or immunomodulatory drug other than interferon alfa or ribavirin for acute or chronic HCV infection including and not restricted to protease or polymerase inhibitors,

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo/PegIFN/RBV (Type: ACTIVE_COMPARATOR): patient to receive two capsules identical to those containing BI201335 once a day for 24 weeks and PegIFN/RBV for 48 weeks
- BI201335 12 weeks (Type: EXPERIMENTAL): patient to receive two capsules containing BI 201335 once a day for 12 weeks and PegIFN/RBV for 48 weeks
- BI201335 24 weeks (Type: EXPERIMENTAL): patient to receive two capsules containing BI 201335 once a day for 24 weeks and PegIFN/RBV for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).